Canada: Patent Subject-Matter Eligibility In Light Of The Revised USPTO Guidance And The Latest Myriad Decision

Last Updated: January 5 2015
Article by Melanie Szweras and Amy Dam

As previously reported ( here), after much consultation from the legal, academic, science and industry communities, the U.S. Patent and Trademark Office ("USPTO") issued earlier this week the Interim Guidance on Patent Subject Matter Eligibility ("Interim Guidance") pursuant to 35 U.S.C. § 101. Effective as of December 16, 2014, the Interim Guidance supplements the June 25, 2014 Preliminary Examination Instructions in view of Alice1, and supersedes the March 4, 2014 Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products issued in view of Myriad2 and Mayo3. In conjunction with the Interim Guidance, new examples relating to nature-based products have replaced the examples in the previous Guidance.  

The Interim Guidance provides some long-awaited positive departure from the previous Guidance; however, this departure is short-lived in light of the latest Myriad decision before the Federal Circuit, In re BRCA1- and BRCA2-based Hereditary Cancer Test Patent Litigation, which may unfortunately bring significant restrictions to diagnostic type method claims (as discussed below). 

The Interim Guidance provides steps for determining subject matter eligibility. Once the Examiner determines that the claim is to a process, machine, manufacture or composition of matter (Step 1), the following two-part analysis for subject matter eligibility ("Mayo test") which was applied in Alice is conducted. 

In Step 2A, the Examiner determines whether the claim is directed to a judicially recognized exception. A first notable departure from the previous Guidance is that the analysis applies to all types of judicial exceptions: laws of nature, natural phenomena and natural products and abstract ideas4 (including software and business methods).

A second notable departure is that a narrower interpretation of a "judicial exception" is adopted in the Interim Guidance and it is no longer required that a claim merely "recite or involve judicial exceptions". To be considered a judicial exception, a claim must be "directed to" a judicial exception, which is a more stringent criterion. 

The Interim Guidance provides insight on how to determine whether the claim is "directed to" a judicial exception in the context of nature-based products. In the March 2014 Guidance examples, only claims presenting structural differences were considered markedly different from products of nature and therefore did not recite or involve a judicial exception. The Interim Guidance now clarifies that "markedly different characteristics" in a product can be expressed as the product's structure, function and/or other properties. If the product is shown to be markedly different by this expanded method, then it is not directed to a judicial exception.

The USPTO's new position is clearly illustrated in its examples of combinations of nature-based products for gunpowder and for a beverage comprising pomelo juice and a preservative. Both mixtures were previously considered non-patent-eligible since combining the substances did not confer a structural difference and therefore had no marked difference from what exists in nature. The USPTO now considers both mixtures patent-eligible, as combining the substances confers a functional difference (i.e. explosiveness and preservative property, respectively) that makes them markedly different from what exists in nature, and therefore not directed to a judicial exception.

Interestingly, the Interim Guidance specifies that the "marked difference" analysis does not apply to a process claim unless it is drafted in such a way that there is no difference in substance from a product claim (e.g. method of providing an apple). This may have a positive effect of broadening the interpretation of patent eligibility in process claims, including method of treatment claims. This is demonstrated in one example where a method of treatment comprised administering an effective amount of purified amazonic acid to a patient suffering from cancer. This method was found to be patent-eligible on the basis that "[a]lthough the claim recites a nature-based product [...], analysis of the claim as a whole indicates that the claim is focused on a process of practically applying the product to treat a particular disease [...], and not on the product per se". 

If the claim is directed to a judicial exception, i.e. no "marked difference" can be found in a nature-based product, the Examiner will then go on to consider whether the claim recites additional elements that amount to "significantly more" than the judicial exception (Step 2B). The previous redundant 12-factor balancing test to determine if the claim recites something "significantly different" has been replaced with a simpler test, where the Examiner will look for limitations that qualify as "significantly more" than the judicial exception. The Interim Guidance lists examples of sufficient limitations, such as: improvements to another technology or technical field; adding a specific limitation other than what is well-understood, routine and conventional in the field, or adding unconventional steps that confine the claim to a particular useful application; and other meaningful limitations beyond generally linking the use of the judicial exception to a particular technological environment.

The new examples provide a patent eligibility analysis of claims directed to products, processes, methods of treatment, purified proteins, genetically modified bacterium, bacterial mixtures, nucleic acids, antibodies, cells and food products. However, the USPTO held off on providing examples on diagnostic method claims possibly because of other pending decisions, including the latest Myriad decision.

Recently, the Federal Circuit rendered its latest decision in the Myriad saga, affirming the District Court's decision to deny Myriad's motion for a preliminary injunction. The Federal Circuit reviewed the claims and found none of them to be patent-eligible. The Court first considered the claims directed to DNA primers. Looking at their structure, it held that they are structurally identical to what is found in nature and rejected the argument that the primers are synthetically replicated or are single stranded. The Court further held that there was no functional difference between primers when extracted and when part of the DNA strand, rejecting the argument that as primers they "have a fundamentally different function than when they are part of the DNA strand".  

Next, the Court looked at the diagnostic method claims. Strangely, instead of analyzing the method claims as a law of nature exception, the Court opined that the claims recite abstract ideas and applied the two-step test used in Alice. In the second step asking "whether the remaining elements, either in isolation or combination with the other non-patent-ineligible elements, are sufficient to "'transform the nature of the claim' into a patent-eligible application"", the Court held that the comparison steps (between wild-type and subject genetic sequences) and the techniques used in making the comparison (hybridizing, detecting, amplification and sequencing steps) "do not add 'enough' to make the claims as a whole patent-eligible" and that further "those comparison techniques were the well-understood, routine, and conventional techniques that a scientist would have thought of when instructed to compare two gene sequences".

Are primers and diagnostic methods still patentable? Possibly, but drafters will have to be mindful to introduce meaningful limitations that are considered "enough" to make the claim as a whole patent-eligible (e.g. claiming primers with labels or tags to distinguish them from what exists in nature). One example of a possible meaningful limitation is to identify the specific mutations that can be detected by the diagnostic test. This limitation was discussed by the Court at the end of the Myriad case, stating that a claim directed to a method of detecting alterations in which the alterations are expressly identified as specific predisposing mutations of the BRCA1 gene sequence might be patent-eligible (although it refused to decide at this time).

The Interim Guidance is a step forward for patentability and for the biotech industry; however, the Myriad decision takes two steps backward. In light of the evolving case law, and in particular, the latest Myriad decision, the USPTO guidelines and claim examples may undergo further revisions, and the IP and life science communities will be surely quick to provide feedback. Written comments on the Interim Guidance as well as additional suggestions on claim examples are currently being accepted, and can be sent to: 2014_interim_guidance@uspto.gov until March 16, 2015.

Footnotes

1. Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. __, 134 S. Ct. 2347 (2014).

2. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. __, 133 S. Ct. 2107 (2013).

3. Mayo Collaborative Serv. v. Prometheus Labs., Inc., 566 U.S. __, 132 S. Ct. 1289 (2012).

4. The USPTO has noted on its website that it will soon publish examples of subject-matter eligibility analysis of abstract ideas, similar to the nature-based product examples.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Melanie Szweras
Amy Dam
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions